M3 Advisory Group LLC Raises Holdings in Johnson & Johnson (NYSE:JNJ)

M3 Advisory Group LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 20.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,591 shares of the company’s stock after acquiring an additional 444 shares during the quarter. M3 Advisory Group LLC’s holdings in Johnson & Johnson were worth $430,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of JNJ. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson during the 4th quarter valued at approximately $36,000. Finally, Highline Wealth Partners LLC raised its position in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on JNJ. Morgan Stanley upped their price target on Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 16th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 5th. Bank of America decreased their target price on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Finally, Barclays decreased their target price on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research report on Thursday, April 17th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Stock Up 1.0%

Johnson & Johnson stock opened at $151.33 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The stock has a market capitalization of $364.11 billion, a price-to-earnings ratio of 16.83, a PEG ratio of 2.27 and a beta of 0.42. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $169.99. The business has a fifty day moving average price of $154.01 and a 200-day moving average price of $153.69.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts’ expectations of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a $1.30 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.44%. Johnson & Johnson’s dividend payout ratio (DPR) is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.